Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion
Ironwood Pharmaceuticals Inc. (IRWD) said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG (VECT) for $17 a share in cash, or a total of about $1 billion, net of VectivBio's cash and debt. The price is equal to a premium of about 80% over the volume-weighted average share price over the previous 90 trading days. VectivBio is a clinical-stage biotech headquartered in Basel and focused on developing treatments for severe, rare conditions, including Short Bowel Syndrome with Intestinal Failure, or SBS-IF, a condition in which the body is unable to absorb nutrients because the small intestine is too short. "SBS-IF is a severe malabsorptive condition requiring ongoing I.V. administration of fluids and nutrients and is associated with significant morbidity and mortality, high economic burden, and an impaired quality of life," the companies said in a joint statement. VectivBio's main investigational therapy apraglutide is a treatment for SBS-IF with data from a Phase 3 trial expected by year-end. Ironwood expects the deal to strengthen its portfolio and boost its per-share earnings by 2026. The deal is expected to close in the second half. VectivBio will hold an extraordinary general meeting of shareholders on June 26 to vote on the deal. VectivBio's stock soared 40% premarket, while Ironwood stock fell 14%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-22-23 0710ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing